Total Funding
95
59
Total FundingPost-IPO Equity raised
Growth Score
6 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
18172
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Derrick Rossi: Founder- Edward Dulac: EVP, CFO, and TreasurerPast Role: Fate Therapeutics, Chief Financial Officer
About the Company
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The
company is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches.
Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts.
Women Founded
